YL-13027 is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase I drugs for Metastatic Adenocarcinoma of The Pancreas have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how YL-13027’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YL-13027 overview
YL-13027 is under development for the treatment of advanced solid tumors including gastrointestinal tract cancer, metastatic pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, head and neck cancer, renal clear cell carcinoma, urinary epithelial carcinoma (transitional cell carcinoma (urothelial cell carcinoma)), chordoma, glioma, meningioma, ependymoma, craniopharyngioma and refractory pituitary tumor. The drug candidate acts by targeting beta isoform of transforming growth factor (TGF-beta). The drug candidate is administered by oral route of administration. It was also under development for multiple myeloma and myelodysplastic syndrome.
The drug candidate was also under development for the treatment of esophageal cancer, gallbladder cancer, lung cancer, gastrointestinal tract cancer and breast cancer.
Shanghai Yingli Pharmaceutical overview
Shanghai Yingli Pharmaceutical (Yingli Pharma) is a clinical-stage biotechnology company that develops oral small-molecule drugs for oncology and metabolic diseases. The company markets its product, Linperslib tablets for the treatment of follicular lymphoma; and is investigating Linperslib drug candidate to treat peripheral t-cell lymphoma. Its pipeline includes YL-13027 for treatment of advanced solid tumors; YL-15293 to treat lung cancer, colorectal cancer, and pancreatic cancer; and YL-17231 for treatment of KRAS mutant tumors. Yingli Pharma is also developing drugs for non-oncology areas including high uric acid and HIPK2 fibrosis treatments. The company operates in China and the US. Yingli Pharma is headquartered in Shanghai, China.
For a complete picture of YL-13027’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
